Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.2580
Abstract: Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide, and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL; however, this combination is toxic for… read more here.
Keywords: rituximab; cll; study; fludarabine cyclophosphamide ... See more keywords